glp-1 and headaches Headache receptor agonists: when medications are therapeutic and when they contribute to the symptom GLP-1 Agonists Can Be Heaven
Description
Duan XY, Liu SY, Yin DG
13 HFpEF with obesity phenotype is characterized by greater symptom severity, worse functional capacity, more adverse hemodynamics, and greater risk of heart failure hospitalization than those with HFpEF without obesity
Even with careful engineering of receptor balance, potency and pharmacokinetics, problems may still crop up, as illustrated by SAR425899s unexpected development failure due to excessive gastrointestinal adverse events during its Phase 2 trials
FDA concerns with unapproved GLP-1 drugs used for weight loss
Mergenthaler P, Lindauer U, Dienel GA, Meisel A
